HRP20140010T1 - Derivati 5-amino-2-(1-hidroksi-etil)-tetrahidropirana - Google Patents
Derivati 5-amino-2-(1-hidroksi-etil)-tetrahidropirana Download PDFInfo
- Publication number
- HRP20140010T1 HRP20140010T1 HRP20140010AT HRP20140010T HRP20140010T1 HR P20140010 T1 HRP20140010 T1 HR P20140010T1 HR P20140010A T HRP20140010A T HR P20140010AT HR P20140010 T HRP20140010 T HR P20140010T HR P20140010 T1 HRP20140010 T1 HR P20140010T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- amino
- methoxy
- pyran
- tetrahydro
- Prior art date
Links
- NUCVOTOKZMPLEM-UHFFFAOYSA-N 1-(5-aminooxan-2-yl)ethanol Chemical class CC(O)C1CCC(N)CO1 NUCVOTOKZMPLEM-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 17
- -1 6,7-dihydro-[1,4]dioxino [2,3-c]pyridazin-3-ylmethyl Chemical group 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- JYSPYEGADQXZPH-VMDGZTHMSA-N (1s)-1-[(2s,5r)-5-(6,7-dihydro-[1,4]oxathiino[2,3-c]pyridazin-3-ylmethylamino)oxan-2-yl]-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethanol Chemical group S1CCOC(N=N2)=C1C=C2CN[C@@H](CO1)CC[C@H]1[C@@H](O)CC1=C(F)C=NC2=CC=C(OC)N=C21 JYSPYEGADQXZPH-VMDGZTHMSA-N 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (17)
1. Spoj, naznačen time, da ima formulu I
[image]
u kojoj
R1 predstavlja alkoksi;
R2 predstavlja H ili F; gdje svaki od R3, R4, R5 i R6 predstavlja neovisno H ili D;
V predstavlja CH i W predstavlja CH ili N, ili V predstavlja N i W predstavlja CH;
Y predstavlja CH ili N;
Z predstavlja O, S ili CH2; i
A predstavlja CH2, CH2CH2 ili CD2CD2;
ili sol takvoga spoja.
2. Spoj formule I prema zahtjevu 1, naznačen time, da svaki od R3, R4, R5 i R6 predstavlja H i A predstavlja CH2 ili CH2CH2;
ili sol takvoga spoja.
3. Spoj formule I prema zahtjevu 1, naznačen time, da
- R1 predstavlja (C1- C3) alkoksi; i
- najviše jedan od R3, R4, R5 i R6 predstavlja D i
A predstavlja CH2 ili CH2CH2, ili svaki od R3, R4, R5 i R6 predstavlja H i A predstavlja CH2,
CH2CH2 ili CD2CD2;
ili sol takvoga spoja.
4. Spoj formule I prema zahtjevu 1 ili 2, naznačen time, da
je to također spoj formule Ip
[image]
u kojoj
R1 predstavlja alkoksi;
R2 predstavlja H ili F;
W predstavlja CH ili N; Y predstavlja CH ili N; Z predstavlja O, S ili CH2;
i n predstavlja 0 ili 1;
ili sol takvoga spoja.
5. Spoj formule I prema jednom od zahtjeva 1 do 4, naznačen time, da
R1 je metoksi;
ili sol takvoga spoja.
6. Spoj formule I prema jednom od zahtjeva 1 do 5, naznačen time, da
R2 predstavlja H;
ili sol takvoga spoja.
7. Spoj formule I prema jednom od zahtjeva 1 do 5, naznačen time, da
R2 predstavlja F;
ili sol takvoga spoja.
8. Spoj formule I prema jednom od zahtjeva 1 do 7, naznačen time, da
Wpredstavlja N;
ili sol takvoga spoja.
9. Spoj formule I prema jednom od zahtjeva 1 do 7, naznačen time, da
Wpredstavlja CH;
ili sol takvoga spoja.
10. Spoj formule I prema jednom od zahtjeva 1 do 9, naznačen time, da
Ypredstavlja CH;
ili sol takvoga spoja.
11. Spoj formule I prema jednom od zahtjeva 1 do 9, naznačen time, da
Ypredstavlja N;
ili sol takvoga spoja.
12. Spoj formule I prema zahtjevu 1, naznačen time, da je on odabran od sljedećih:
-(1S)-1-{(1S,5R)-5-[(2,3-dihidro-[1,4]dioksino[2,3-c]piridin-7-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(6-metoksi-[1,5]naftiridin-4-il)-etanol;
-(1S)-1-{(2S,5R)-5-[(6,7-dihidro-[1,4]dioksino[2,3-c]piridazin-3-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(6-metoksi-[1,5]naftiridin-4-il)-etanol;
-(1S)-1-{(2S,5R)-5-[(2,3-dihidro-[1,4]dioksino[2,3-c]piridin-7-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(3-fluoro-6-metoksi-[1,5]naftiridin-4-il)-etanol;
-(1S)-1-{(2S,5R)-5-[(6,7-dihidro-[1,4]dioksino [2,3-c]piridazin-3-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(3-fluoro-6-metoksi-[1,5]naftiridin-4-il)-etanol;
-(1S)-1-{(2S,5R)-5-[(2,3-dihidro-[1,4]dioksino[2,3-c]piridin-7-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(7-fluoro-2-metoksi-kinolin-8-il)-etanol;
-(1S) -1-{(2S,5R)-5-[(2,3-dihidro-4-oksa-1-tia-6-aza-naftalen-7-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(3-fluoro-6-metoksi-[1,5]naftiridin-4-il)-etanol;
-(1S)-1-{(2S,5R)-5-[(2,3-dihidro-4-oksa-1-tia-6-aza-naftalen-7-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(7-fluoro-2-metoksi-kinolin-8-il)-etanol;
-(1S)-2-(3-fluoro-6-metoksi-[1,5]naftiridin-4-il)-1-{(2S,5R)-5-[(3-oksa-1-tia-5-aza-indan-6-ilmetil)-amino]-tetrahidro-piran-2-il}-etanol;
-(1S)-2-(7-fluoro-2-metoksi-kinolin-8-il)-1-{(2S,5R)-5-[(3-oksa-1-tia-5-aza-indan-6-ilmetil)-amino]-tetrahidro-piran-2-il}-etanol;
-(1S)-1-{(2S,5R)-5-[(3,4-dihidro-2H-pirano[2,3-c]piridin-6-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(3-fluoro-6-metoksi-[1,5]naftiridin-4-il)-etanol;
-(1S)-1-{(2S,5R)-5-[(6,7-dihidro-8-oksa-5-tia-1,2-diaza-naftalen-3-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(3-fluoro-6-metoksi-[1,5]naftiridin-4-il)-etanol;
-(1S)-1-{(2S,5R)-5-[(2,3-dihidro-[1,4]dioksino[2, 3-c]piridin-7-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(6-fluoro-3-metoksi-kinoksalin-5-il)-etanol;
-(1S)-1-{(2S,5R)-5-[(6,7-dihidro-[1,4]dioksino[2,3-c]piridazin-3-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(6-fluoro-3-metoksi-kinoksalin-5-il)-etanol;
-(1S)-1-{(2S,5R)-5-[(2,3-dihidro-4-oksa-1-tia-6-aza-naftalen-7-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(6-fluoro-3-metoksi-kinoksalin-5-il)-etanol;
-(1S)-1-{(2S,5R)-5-[(6,7-dihidro-8-oksa-5-tia-1,2-diaza-naftalen-3-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(6-fluoro-3-metoksi-kinoksalin-5-il)-etanol;
-(1S)-1-((2S,5R)-5-(((2,3-dihidro-[1,4]dioksino[2,3-c]piridin-7-il)metil-d1)amino)tetrahidro-2H-piran-2-il)-2-(3-fluoro-6-metoksi-1,5-naftiridin-4-il) etanol;
-(1S)-1-((2S,5R)-5-(((2,3-dihidro-[1,4]dioksino-2,2,3,3-d4-[2,3-c]piridin-7-il) metil)amino) tetrahidro-2H-piran-2-il)-2-(3-fluoro-6-metoksi-1,5-naftiridin-4-il)-etanol;
-(1S)-1-((2S,SR)-5-(((2,3-dihidro-[1,4]dioksino[2,3-c]piridin-7-il)metil)amino)tetrahidro-2H-piran-2-il)-2-(3-fluoro-6-metoksi-1,5-naftiridin-4-il)etanol-1-d1;
-(S)-1-((2S,5R)-5-(((2,3-dihidro-[1,4]oksatiino[2,3-c]piridin-7-il)metil-d1)amino)tetrahidro-2H-piran-2-il)-2-(3-fluoro-6-metoksi-1,5-naftiridin-4-il)-etanol;
-(1S)-1-((2S,5R)-5-(((2,3-dihidro-[1,4]dioksino-[2,3-c]piridin-7-il)metil)amino)tetrahidro-2H-piran-2-il)-2-(3-fluoro-6-metoksi-1,5-naftiridin-4-il)-etanol-2-d1;
-(S)-1-((2S,5R)-5-(((2,3-dihidro-[1,4]oksatiino[2,3-c]piridin-7-il)metil)amino)tetrahidro-2H-piran-2-il)-2-(3-fluoro-6-metoksi-1,5-naftiridin-4-il)-etanol-2-d1;
-(S)-1-((2S,5R)-5-(((2,3-dihidro-[1,4]oksatiino[2,3-c]piridin-7-il)metil)amino)tetrahidro-2H-piran-2-il)-2-(3-fluoro-6-metoksi-1,5-naftiridin-4-il)-etanol-1-d1;
-(S)-1-{(2S,SR)-5-[(6,7-dihidro-8-oksa-5-tia-1,2-diaza-naftalen-3-ilmetil-d1)-amino]-tetrahidro-piran-2-il}-2-(3-fluoro-6-metoksi-[1,5]naftiridin-4-il)-etanol;
-(1S)-1-((2S,5R)-5-(((2,3-dihidro-[1,4]dioksino[2,3-c]piridin-7-il)metil-d2)amino)tetrahidro-2H-piran-2-il)-2-(3-fluoro-6-metoksi-1,5-naftiridin-4-il)-etanol;
ili sol takvoga spoja.
13. Spoj formule I prema zahtjevu 1, naznačen time, da je on
(1S)-1-{(2S,5R)-5-[(6,7-dihidro-8-oksa-5-tia-1,2-diaza-naftalen-3-ilmetil)-amino]-tetrahidro-piran-2-il}-2-(3-fluoro-6-metoksi-[1,5]naftiridin-4-il)-etanol;
ili sol takvoga spoja.
14. Spoj formule I prema jednom od zahtjeva 1 do 13, ili njegova farmacutski prihvatljiva sol, naznačen(a) time, da se upotrebljava kao lijek.
15. Farmaceutski sastav, naznačen time, da kao djelotvorni sastojak sadrži spoj formule I prema jednom od zahtjeva 1 do 13 ili njegovu farmaceutski prihvatljivu sol te najmanje jedno terapeutski inertno pomoćno sredstvo.
16. Uporaba spoja formule I prema jednom od zahtjeva 1 do 13 ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za sprečavanje ili liječenje bakterijske infekcije.
17. Spoj formule I prema jednom od zahtjeva 1 do 13 ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava za sprečavanje ili liječenje bakterijske infekcije.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2008055261 | 2008-12-12 | ||
| PCT/IB2009/055689 WO2010067332A1 (en) | 2008-12-12 | 2009-12-11 | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140010T1 true HRP20140010T1 (hr) | 2014-02-14 |
Family
ID=41723046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140010AT HRP20140010T1 (hr) | 2008-12-12 | 2014-01-07 | Derivati 5-amino-2-(1-hidroksi-etil)-tetrahidropirana |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8211890B2 (hr) |
| EP (1) | EP2376497B1 (hr) |
| JP (1) | JP4955835B2 (hr) |
| KR (1) | KR101297450B1 (hr) |
| CN (1) | CN102232078B (hr) |
| AR (1) | AR074604A1 (hr) |
| AU (1) | AU2009325902B2 (hr) |
| BR (1) | BRPI0924081A2 (hr) |
| CA (1) | CA2744456C (hr) |
| CL (1) | CL2011001413A1 (hr) |
| CY (1) | CY1114869T1 (hr) |
| DK (1) | DK2376497T3 (hr) |
| ES (1) | ES2435596T3 (hr) |
| HK (1) | HK1162478A1 (hr) |
| HR (1) | HRP20140010T1 (hr) |
| IL (1) | IL213432A (hr) |
| MA (1) | MA32956B1 (hr) |
| MX (1) | MX2011005905A (hr) |
| MY (1) | MY159183A (hr) |
| NZ (1) | NZ593891A (hr) |
| PL (1) | PL2376497T3 (hr) |
| PT (1) | PT2376497E (hr) |
| RU (1) | RU2525541C2 (hr) |
| SG (1) | SG172088A1 (hr) |
| SI (1) | SI2376497T1 (hr) |
| TW (1) | TWI426076B (hr) |
| WO (1) | WO2010067332A1 (hr) |
| ZA (1) | ZA201105095B (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR076222A1 (es) | 2009-04-09 | 2011-05-26 | Actelion Pharmaceuticals Ltd | Derivados 2-hidroxietil-1h-quinolin-ona y sus analogos azaisotericos con actividad antibacteriana y composiciones farmaceuticas que los contienen |
| ES2578182T3 (es) | 2011-05-31 | 2016-07-21 | Actelion Pharmaceuticals Ltd. | Procedimientos de preparación de intermediarios sintéticos que pueden usarse para la fabricación de antibióticos |
| WO2013003383A1 (en) * | 2011-06-27 | 2013-01-03 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
| WO2013038374A1 (en) | 2011-09-16 | 2013-03-21 | Actelion Pharmaceuticals Ltd | Process for manufacturing a synthetic intermediate |
| AR089929A1 (es) | 2012-02-10 | 2014-10-01 | Actelion Pharmaceuticals Ltd | Proceso para manufacturar un derivado de naftiridina |
| AR090844A1 (es) * | 2012-04-27 | 2014-12-10 | Actelion Pharmaceuticals Ltd | Proceso para elaborar derivados de naftiridina |
| TW201722965A (zh) * | 2015-08-16 | 2017-07-01 | 葛蘭素史密斯克藍智慧財產發展有限公司 | 用於抗菌應用之化合物 |
| TW201833120A (zh) | 2017-02-17 | 2018-09-16 | 瑞士商愛杜西亞製藥有限公司 | 芳基噁唑啶酮抗生素化合物 |
| CR20200054A (es) | 2017-08-09 | 2020-03-21 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| PL3676297T3 (pl) * | 2017-09-01 | 2023-12-11 | Denali Therapeutics Inc. | Związki, kompozycje i sposoby |
| CR20210426A (es) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1095611A1 (ru) * | 1982-09-10 | 2007-06-27 | Краснодарский ордена Трудового Красного Знамени политехнический институт | Хлорид 5-хлорметил-2-этил-8-метил-4Н-м-диоксино-(4,5-с)-пиридиния, обладающий антимикробной активностью |
| CZ289756B6 (cs) * | 1991-03-28 | 2002-04-17 | Eisai Co., Ltd. | Heterocyklicko-cyklické aminové deriváty, meziprodukty postupu přípravy těchto sloučenin, farmaceutický prostředek a pouľití uvedených derivátů |
| GB9822450D0 (en) | 1998-10-14 | 1998-12-09 | Smithkline Beecham Plc | Medicaments |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| TW200406410A (en) * | 2002-01-29 | 2004-05-01 | Glaxo Group Ltd | Compounds |
| AR040336A1 (es) * | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto |
| AR042486A1 (es) | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . |
| DE10316081A1 (de) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US20070254872A1 (en) | 2004-07-08 | 2007-11-01 | Glaxo Group Limited | Antibacterial Agents |
| CA2580621A1 (en) * | 2004-09-24 | 2006-03-30 | Actelion Pharmaceuticals Ltd | New bicyclic antibiotics |
| JP5314244B2 (ja) | 2004-10-27 | 2013-10-16 | 富山化学工業株式会社 | 新規な含窒素複素環化合物およびその塩 |
| AU2006250987A1 (en) * | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| WO2007016610A2 (en) * | 2005-08-02 | 2007-02-08 | Glaxo Group Limited | Antibacterial agents |
| DK1954697T3 (da) | 2005-10-21 | 2010-06-14 | Glaxo Group Ltd | Peri-kondenserede tricykliske forbindelser, der er anvendelige som antibakterielle midler |
| DE602006013878D1 (de) | 2005-12-22 | 2010-06-02 | Glaxo Group Ltd | Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel |
| DE102005062889A1 (de) | 2005-12-29 | 2007-07-05 | Robert Bosch Gmbh | Elektrische Null-Kraft-Steckvorrichtung |
| JP2009524643A (ja) * | 2006-01-26 | 2009-07-02 | アクテリオン ファーマシューティカルズ リミテッド | テトラヒドロピラン抗生物質 |
| CN101400674A (zh) | 2006-03-10 | 2009-04-01 | 埃科特莱茵药品有限公司 | 抗生素化合物 |
| JP2009532423A (ja) | 2006-04-06 | 2009-09-10 | グラクソ グループ リミテッド | 抗菌剤としてのピロロ−キノキサリノン誘導体 |
| GB0613208D0 (en) | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
| EP1992628A1 (en) | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
| CL2008001003A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| EP2167494B1 (en) * | 2007-06-15 | 2011-08-17 | Actelion Pharmaceuticals Ltd. | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives |
| CN101874032B (zh) | 2007-11-26 | 2013-02-06 | 富山化学工业株式会社 | 二氮杂萘衍生物一水合物及其制备方法 |
-
2009
- 2009-12-11 CN CN200980148242.2A patent/CN102232078B/zh active Active
- 2009-12-11 MA MA34003A patent/MA32956B1/fr unknown
- 2009-12-11 CA CA2744456A patent/CA2744456C/en active Active
- 2009-12-11 AU AU2009325902A patent/AU2009325902B2/en not_active Ceased
- 2009-12-11 RU RU2011128550/04A patent/RU2525541C2/ru not_active IP Right Cessation
- 2009-12-11 TW TW098142582A patent/TWI426076B/zh not_active IP Right Cessation
- 2009-12-11 US US13/139,179 patent/US8211890B2/en active Active
- 2009-12-11 SG SG2011042611A patent/SG172088A1/en unknown
- 2009-12-11 SI SI200930791T patent/SI2376497T1/sl unknown
- 2009-12-11 PT PT97968192T patent/PT2376497E/pt unknown
- 2009-12-11 MX MX2011005905A patent/MX2011005905A/es active IP Right Grant
- 2009-12-11 KR KR1020117015370A patent/KR101297450B1/ko active IP Right Grant
- 2009-12-11 EP EP09796819.2A patent/EP2376497B1/en active Active
- 2009-12-11 ES ES09796819T patent/ES2435596T3/es active Active
- 2009-12-11 PL PL09796819T patent/PL2376497T3/pl unknown
- 2009-12-11 AR ARP090104821A patent/AR074604A1/es not_active Application Discontinuation
- 2009-12-11 BR BRPI0924081A patent/BRPI0924081A2/pt active Search and Examination
- 2009-12-11 WO PCT/IB2009/055689 patent/WO2010067332A1/en active Application Filing
- 2009-12-11 NZ NZ593891A patent/NZ593891A/xx not_active IP Right Cessation
- 2009-12-11 DK DK09796819.2T patent/DK2376497T3/da active
- 2009-12-11 JP JP2011540318A patent/JP4955835B2/ja active Active
- 2009-12-11 MY MYPI2011002646A patent/MY159183A/en unknown
-
2011
- 2011-06-09 IL IL213432A patent/IL213432A/en not_active IP Right Cessation
- 2011-06-10 CL CL2011001413A patent/CL2011001413A1/es unknown
- 2011-07-11 ZA ZA2011/05095A patent/ZA201105095B/en unknown
-
2012
- 2012-03-16 HK HK12102672.7A patent/HK1162478A1/xx not_active IP Right Cessation
-
2013
- 2013-12-18 CY CY20131101136T patent/CY1114869T1/el unknown
-
2014
- 2014-01-07 HR HRP20140010AT patent/HRP20140010T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140010T1 (hr) | Derivati 5-amino-2-(1-hidroksi-etil)-tetrahidropirana | |
| US7605169B2 (en) | Antibacterial agents | |
| HRP20110005T1 (hr) | Spoj tricikličkog benzopirana kao anti-aritmijskog sredstva | |
| HRP20160725T1 (hr) | Biciklični heterociklični derivati kao inhibitori fgfr kinaze za primjenu u terapiji | |
| WO2004072086A3 (en) | Antiparasitic terpene alkaloids | |
| PL373414A1 (en) | 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands | |
| ZA200405336B (en) | Urea substituted imidazopyridines | |
| WO2007039740A3 (en) | Preparation and use of tetrahydropyrrolo [3, 2-c] pyridin-4-one derivatives for treatment of obesity, psychiatric and neurological disorders | |
| EA200200337A1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[4,3-d]ПИРИМИДИНА | |
| MXPA03005464A (es) | Agentes antivirales. | |
| JP2005527472A5 (hr) | ||
| WO1992001675A3 (en) | Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene b4 antagonist activity, their preparation and use in pharmaceutical compositions | |
| EP1277741A4 (en) | CYCLE CONNECTIONS | |
| RU98101135A (ru) | Новые аналоги камптотецина, способы получения, их применение в качестве лекарственных средств и содержащие их фармацевтические композиции | |
| BRPI0517425A (pt) | composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto | |
| EA200700144A1 (ru) | Производные пиридопиримидина, их получение, их применение в терапии | |
| WO2007083188A3 (en) | Improved process for the preparation of an optically active 5h-pyrrolo [3,4-b] pyrazine derivative | |
| WO2005118579A3 (en) | Thiazole derivatives as chemokine receptor antagonists | |
| PE20061110A1 (es) | Derivados de imidazopiridina como antagonistas de la bomba de acido (apa) | |
| JPWO2006137527A1 (ja) | チアゾール誘導体 | |
| AU2018240031A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| KR960704890A (ko) | 이미다조[1,2-a] 피리딘의 알콕시알킬 카르바메이트 (ALKOXY ALKYL CARBAMATES FROM IMIDAZO [1,2-a] PYRIDINES) | |
| EP3068387A1 (en) | Compounds and methods for the treatment of malaria | |
| MY122042A (en) | Pro-drugs and counterparts of camptothecin, their application as medicines | |
| KR20190042752A (ko) | 세펨 화합물, 그의 제조 및 용도 |